Shahzad Raza, MD, discusses new data from the phase 2 RedirecTT-1 study of talquetamab with teclistamab for the treatment of patients with relapsed/refractory multiple myeloma and extramedullary ...

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell ...

During a live event, Taewoong Choi, MD, discussed the potential use of quadruplet in transplant-ineligible multiple myeloma ...

A study reveals significant genomic differences in metastatic prostate cancer among veterans, highlighting the need for ...

Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Combination therapy with savolitinib and osimertinib shows promising results in treating advanced NSCLC with EGFR mutations ...

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and ...